- Histologically or cytologically confirmed adenocarcinoma of the prostate without evidence of small cell carcinoma or greater than 50% neuroendocrine differentiation.. Metastatic disease must be present including soft tissue and/or bone metastases prior to study enrollment. Regional lymph node involvement must be accompanied by at least one additional site of disease including visceral, non-regional nodal or skeletal metastases.